

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of the claims in the application:

Listing of Claims:

1. (Currently Amended) A medical article[[,]] comprising a coating disposed on at least a portion of an implantable medical device, the coating comprising:

(a) a fluorinated polymer; and

(b) a biologically beneficial polymer,

~~wherein the fluorinated polymer is selected from:~~

~~(i) products of polymerization of fluorinated olefins;~~

~~(ii) fluorine-containing cyclic polymers having a main chain with an asymmetrical cyclic structure selected from a group of polymers of repeating units of cyclically polymerized perfluorallyl vinyl ether, perfluorobutenyl vinyl ether, and a combination thereof; and~~

~~(iii) copolymers of perfluoro-2,2-dimethyl-1,3-dioxole with perfluoroolefins or with perfluoro(alkyl vinyl) ethers,~~

wherein the biologically beneficial polymer is selected from the group consisting of hyaluronic acid, phosphoryl choline, poly(ethylene oxide-co-propylene oxide), polyaspirin, and poly(ester amide) polymers, and

wherein the biologically beneficial polymer is conjugated to a biologically active agent.

2. (Original) The medical article of Claim 1, wherein the implantable medical device is a stent.

3. (Currently Amended) The medical article of Claim 1, wherein the fluorinated polymer is selected from the group consisting of products of polymerization of fluorinated olefins.

4. (Original) The medical article of Claim 3, wherein the products of polymerization of fluorinated olefins are selected from a group consisting of poly(vinylidene fluoride-co-hexafluoropropene), poly(tetrafluoroethylene), fluorinated poly(ethylene-co-propylene), poly(hexafluoropropene), poly(chlorotrifluoroethylene), poly(vinylidene fluoride), poly(vinylidene fluoride-co-tetrafluoroethylene), poly(tetrafluoroethylene-co-hexafluoropropene), poly(tetrafluoroethylene-co-vinyl alcohol), poly(tetrafluoroethylene-co-vinyl acetate), poly(tetrafluoroethylene-co-propene), poly(hexafluoropropene-co-vinyl alcohol), poly(ethylene-co-tetrafluoroethylene), poly(ethylene-co-hexafluoropropene), and poly(vinylidene fluoride-co-chlorotrifluoroethylene).


5. (Currently Amended) The medical article of Claim 3, wherein the fluorinated polymer is selected from the group consisting of copolymers of perfluoro-2,2-dimethyl-1,3-dioxole with perfluoroolefins or with perfluoro(alkyl vinyl) ethers.

6. (Currently Amended) The medical article of Claim 1, wherein the fluorinated polymer is selected from a group consisting of polymers of repeating units of cyclically polymerized perfluorallyl vinyl ether, perfluorobutenyl vinyl ether, and a combination thereof.




7. (Currently Amended) The medical article of Claim 1, wherein the biologically beneficial polymer is selected from a group consisting of hyaluronic acid, phosphoryl choline, polyaspirin, and ~~poly(ester amides)~~poly(ester amide) polymers.

8. (Currently Amended) The medical article of Claim 7, wherein the poly(ester amide) polymers are~~poly(ester amides) include~~ polymers having at least one ester bond and at least one amide bond.




9. (Currently Amended) The medical article of Claim 7, wherein the poly(ester amide) polymers are~~the poly(ester amides) include~~ polymers ~~having~~ of a general formula $-\text{[M-P]}_m-\text{[M-Q]}_n-$, wherein M is a moiety represented by the structure



P is a moiety selected from a group (P1)-(P4) consisting of:



Q is a moiety selected from a group (Q1)-(Q4) consisting of:



wherein:

R₁ is selected from a group consisting of a straight chained or branched aliphatic alkylene group C_rH_{2r}, wherein r is an integer having the value between 2 and 12, and an aromatic group;

R₂ is selected from a group consisting of hydrogen, methyl, *iso*-propyl, *sec*-butyl, *iso*-butyl, and benzyl;

R₃ is selected from a group consisting of methylene, methylenemethylene, *n*-propylene, *iso*-propylene, ethylenemethylene, straight chained or branched butylene, and *n*-amylene;

X is a straight chained or branched aliphatic alkylene group C_xH_{2x}, wherein x is an integer between 2 and 12;


Y is a straight chained or branched aliphatic alkylene group C_yH_{2y}, wherein y is 2, 4, or 5;

Z is a biologically beneficial moiety derived from ~~PEG~~poly(ethylene glycol), poly(propylene glycol), hyaluronic acid, poly(2-hydroxyethyl methacrylate), and

m and n are integers.

10. (Currently Amended) The medical article of Claim 7, wherein the poly(ester amide) polymers are ~~the poly(ester amide) is a product~~products of reaction between a diol-diamine and a dicarboxylic acid.

11. (Currently Amended) The medical article of Claim 7, wherein the poly(ester amide) polymers are ~~poly(ester amide) is a polymer that includes~~ polymers of a formula comprising a unit having of the formula:



wherein R is selected from a group consisting of ~~hydrogen, hydrogen,~~ methyl, *iso*-propyl, *sec*-butyl, *iso*-butyl, and benzyl; x is an integer having a value between 2 and 12; and y is an integer having a value between 1 and 12.

12. (Cancelled)

13. (Currently Amended) The medical article of Claim 1, wherein the biologically active agent is selected from the group consisting of polyarginine, cRGD peptide, antisense agent Rensten-NG, rapamycin, everolimus (40-*O*-(2-hydroxy)ethyl-rapamycin), 40-*O*-(3-hydroxy)propyl-rapamycin, 40-*O*-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-*O*-tetrazole-rapamycin, and diazenium diolates.

14. – 26. (Cancelled)

27. (Currently Amended) The medical article of Claim 13, wherein the diazenium diolates are selected from the group consisting of 1,3-propanediamine, N-{4-[1-(3-aminopropyl)-2-hydroxy-2-nitrosohydrazino]butyl}-diazen-1-ium-1,2-diolate (SDD), 1-{N-methyl-N-[6-(N-methylammonio)hexyl]amino}diazen-1-ium-1,2-diolate (MAHMA-NO), and Z-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NO).

28. (Withdrawn) The medical article of claim 1, wherein the fluorinated polymer is selected from a group consisting of poly(tetrafluoroethylene-co-vinyl alcohol), poly(tetrafluoroethylene-co-vinyl acetate), poly(tetrafluoroethylene-co-propene), poly(hexafluoropropene-co-vinyl alcohol), poly(ethylene-co-tetrafluoroethylene), and poly(ethylene-co-hexafluoropropene), and wherein the biobeneficial polymer is poly(ester amide).

29. (New) The medical article of claim 1, wherein the fluorinated polymer is selected from the group consisting of:

(i) products of polymerization of fluorinated olefins;

(ii) fluorine-containing cyclic polymers having a main chain with an asymmetrical cyclic structure selected from the group consisting of polymers of repeating units of cyclically polymerized perfluorallyl vinyl ether, perfluorobutenyl vinyl ether, and a combination thereof; and

(iii) copolymers of perfluoro-2,2-dimethyl-1,3-dioxole with perfluoroolefins or with perfluoro(alkyl vinyl) ethers.

30. (New) The medical article of claim 1, wherein the coating comprises two or more layers, the fluorinated polymer and the biobeneficial polymer being in separate layers, and the outermost layer comprising the biobeneficial polymer.

31. (New) The medical article of claim 1, wherein the biologically active agent is selected from the group consisting of rapamycin, everolimus (40-*O*-(2-hydroxy)ethyl-rapamycin), 40-*O*-(3-hydroxy)propyl-rapamycin, 40-*O*-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-*O*-tetrazole-rapamycin.

32. (New) The medical article of claim 31, wherein the outermost layer of the coating covers the entire surface area of the implantable device.

33. (New) A medical article comprising a coating disposed on at least a portion of an implantable medical device, the coating comprising:

(a) a fluorinated polymer; and

(b) a biologically beneficial polymer;

wherein the fluorinated polymer is selected from the group consisting of:

(i) products of polymerization of fluorinated olefins;

(ii) fluorine-containing cyclic polymers having a main chain with an asymmetrical cyclic structure selected from a group consisting of polymers of repeating units of cyclically polymerized perfluorallyl vinyl ether, perfluorobutenyl vinyl ether, and a combination thereof; and

(iii) copolymers of perfluoro-2,2-dimethyl-1,3-dioxole with perfluoroolefins or with perfluoro(alkyl vinyl) ethers;

wherein the biologically beneficial polymer is selected from the group consisting of hyaluronic acid, phosphoryl choline, poly(ethylene oxide-co-propylene oxide), polyaspirin, and poly(ester amide) polymers;

and

wherein the biologically beneficial polymer is conjugated to a biologically active agent.